Adefovir dipivoxil (adefovir) — Competitive Intelligence Brief

Adefovir dipivoxil (adefovir) (Adefovir dipivoxil (adefovir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleotide reverse transcriptase inhibitor. Area: Virology / Infectious Disease.

marketed Nucleotide reverse transcriptase inhibitor Hepatitis B virus reverse transcriptase / DNA polymerase Virology / Infectious Disease Small molecule

Target snapshot

Adefovir dipivoxil (adefovir) (Adefovir dipivoxil (adefovir)) — Merck Sharp & Dohme LLC. Adefovir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral DNA polymerase activity in hepatitis B virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adefovir dipivoxil (adefovir) TARGET	Adefovir dipivoxil (adefovir)	Merck Sharp & Dohme LLC	marketed	Nucleotide reverse transcriptase inhibitor	Hepatitis B virus reverse transcriptase / DNA polymerase
atazanavir/tenofovir/emtricitabine	atazanavir/tenofovir/emtricitabine	Community Research Initiative of New England	marketed	Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Tenofovir (TDF)	Tenofovir (TDF)	French National Agency for Research on AIDS and Viral Hepatitis	marketed	Nucleotide reverse transcriptase inhibitor (NtRTI)	HIV reverse transcriptase; Hepatitis B polymerase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
Emtricitabine/tenofovir disoproxil fumarate	Emtricitabine/tenofovir disoproxil fumarate	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI/NtRTI) combination	HIV-1 reverse transcriptase
Vaginal TFV Gel	Vaginal TFV Gel	University of Washington	marketed	Nucleotide reverse transcriptase inhibitor (microbicide)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleotide reverse transcriptase inhibitor class)

1. GlaxoSmithKline · 2 drugs in this class
2. IlDong Pharmaceutical Co Ltd · 1 drug in this class
3. Bristol-Myers Squibb · 1 drug in this class
4. Merck Sharp & Dohme LLC · 1 drug in this class
5. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
6. Sun Yat-sen University · 1 drug in this class
7. Jiangxi Kvvit Pharmaceutical Co., Ltd. · 1 drug in this class